---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-002398"
form_type: "8-K"
ticker: "CTMX"
cik: "0001501989"
company_name: "CytomX Therapeutics, Inc."
filed_at: "2023-01-05T23:59:59+00:00"
generated_at: "2026-06-20T19:34:12.625452+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# CytomX inks $35M upfront deal with Moderna for mRNA-Probody therapies; milestones up to $1.2B

## Summary
- Upfront payment of $35M includes $5M pre-paid research funding; potential milestones total $1.2B.
- Tiered royalties on net sales from high single digit to low-teen percentages per licensed product.
- Moderna gets exclusive worldwide license to CytomX Probody platform for mRNA-encoded conditionally-activated therapies.
- Moderna has a one-time option to participate in a future CytomX equity financing.
- Collaboration covers oncology and non-oncology programs; Moderna can terminate on product-by-product basis after 2 years.

## SEC filing metadata
- accession: 0001193125-23-002398
- form_type: 8-K
- ticker: CTMX
- cik: 0001501989
- company_name: CytomX Therapeutics, Inc.
- filed_at: 2023-01-05T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501989/000119312523002398/0001193125-23-002398-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501989/000119312523002398/d405031d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-002398
- JSON: https://secwatch.observer/filing/0001193125-23-002398.json
- Plain text: https://secwatch.observer/filing/0001193125-23-002398.txt

## Key facts
- Material Agreements
  CytomX Therapeutics, Inc. entered into Collaboration and License Agreement with ModernaTX, Inc., a wholly-owned subsidiary of Moderna, Inc. valued at $35 million (effective 2022-12-30).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: ModernaTX, Inc., a wholly-owned subsidiary of Moderna, Inc.
  - Value: $35 million
  - Effective: 2022-12-30
  source text: On December 30, 2022, CytomX Therapeutics, Inc. (the “Company”) entered into a Collaboration and License Agreement (the “Collaboration and License Agreement”) with ModernaTX, Inc., a wholly-owned subsidiary of Moderna, Inc. (“Moderna”),
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501989/000119312523002398/0001193125-23-002398-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.